Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia

Gene Therapy

Volumn 12, Issue 23, 2005, Pages 1707-1717

  Zibert, A ^a   Thomassen, A ^a   Muller L ^a   Nguyen, L ^a   Glouchkova, L ^a   Fraefel, C ^b   Roskrow, M ^c   Meisel, R ^a   Dilloo, D ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Herpesvirus; HSV; Leukemia lymphoma; Tumor vaccination; Vector

Indexed keywords

ANTILEUKEMIC AGENT; CANCER VACCINE; CD70 ANTIGEN; HERPESVIRUS VECTOR; INTERLEUKIN 2; VIRUS PROTEIN; VIRUS RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMPLICON; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CELL LINE; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFICACY; FEMALE; GENETIC TRANSDUCTION; HELPER VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; TRANSGENE; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD70; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GENE THERAPY; GENES, MHC CLASS I; GENETIC ENGINEERING; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LEUKEMIA, LYMPHOCYTIC, ACUTE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTORS;

ANIMALIA; HERPESVIRIDAE; HUMAN HERPESVIRUS 1;

EID: 27944507757     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302577     Document Type: Article

References (60)

1. Glorioso JC, Mata M, Fink DJ. Therapeutic gene transfer to the nervous system using viral vectors. J Neurovirol 2003;9:165-172.
2. Whitley RJ. Herpes simplex viruses. In: Knippe D, Howley R (eds). Virology. Lippincott Williams & Wilkins: Philadelphia, PA, 2001, pp 2461-2509.
3. Dilloo D et al. A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood 1997; 89: 119-127.
4. Kutubuddin M et al. Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 1999; 93: 643-654.
5. Tolba KA et al. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood 2001; 98: 287-295.
6. Sena-Esteves M, Saeki Y, Fraefel C, Breakefield XO. HSV-1 amplicon vectors - simplicity and versatility. Mol Ther 2000; 2: 9-15.
7. Dilloo D et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996; 2: 1090-1095.
8. Dunussi-Joannopoulos K, Weinstein HJ, Arceci RJ, Croop JM. Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model. J Pediatr Hematol Oncol 1997; 19: 536-540.
9. Nakazaki Y et al. Vaccine effect of granulocyte-macrophage colony-stimulating factor or CD80 gene-transduced murine hernatopoietic tumor cells and their cooperative enhancement of antitumor immunity. Gene Therapy 1998; 5: 1355-1362.
10. Stripecke R et al. Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia. Hum Gene Ther 1999; 10: 2109-2122.
11. Vereecque R et al. Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Gene Therapy 2000; 7: 1312-1316.
12. Herold BC et al. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B. J Gen Virol 1994; 75 (Part 6): 1211-1292.
13. Spear PG et al. Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. Adv Exp Med Biol 1992; 313: 341-353.
14. Geraghty RJ et al. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 1998; 280: 1618-1620.
15. WuDunn D, Spear PG. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 1989; 63: 52-58.
16. Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996; 87: 427-436.
17. Mauri DN et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998; 8: 21-30.
18. Warner MS et al. A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology 1998; 246: 179-189.
19. Spaete RR, Frenkel N. The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30: 295-304.
20. Saeki Y et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: Rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1998; 9: 2787-2794.
21. Stavropoulos TA, Strathdee CA. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 1998; 72: 7137-7143.
22. Horsburgh BC et al. Allele replacement: An application that permits rapid manipulation of herpes simplex virus type 1 genomes. Gene Therapy 1999; 6: 922-930.
23. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
24. Barcy S, Corey L. Herpes simplex inhibits the capacity of lymphoblastoid B cell lines to stimulate CD4+ T cells. J Immunol 2001; 166: 6242-6249.
25. Samady L et al. Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: Potential of vhs-HSV vectors for dendritic cell-mediated immunotherapy. J Virol 2003; 77: 3768-3776.
26. Fruh K et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995; 375: 415-418.
27. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491-502.
28. Eling DJ et al. Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A. Gene Therapy 2000; 7: 1210-1216.
29. Hill A et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375: 411-415.
30. Schwartz RH, Mueller DL, Jenkins MK, Quill H. T-cell clonal anergy. Cold Spring Harb Symp Quant Biol 1989; 54(Part 2): 605-610.
31. Trentin L et al. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res 1997; 57: 4940-4947.
32. Tsukada N et al. The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. J Exp Clin Cancer Res 1997; 16: 171-176.
33. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999; 162: 5003-5010.
34. Dilloo D et al. CD40 ligand induces an antileukemia immune response in vivo. Blood 1997; 90: 1927-1933.
35. Goodwin RG et al. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 1993; 73: 447-456.
36. Hintzen RQ et al. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol 1994; 152: 1762-1773.
37. Kobata T et al. CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation. J Immunol 1994; 153: 5422-5432.
38. Brown GR, Meek K, Nishioka Y, Thiele DL. CD27-CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes. J Immunol 1995; 154: 3686-3695.
39. Hintzen RQ et al. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol 1995; 154: 2612-2623.
40. Couderc B et al. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther 1998; 5: 163-175.
41. Lorenz MG, Kantor JA, Schlom J, Hodge JW. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther 1999; 10: 1095-1103.
42. Zibert A et al. Leukemia cells transduced with HSV-1 amplicons expressing CD70 and IL-2 stimulate a protective anti-leukemic immune response. Blood 2000; 96: 804a.
43. Matzinger P. An innate sense of danger. Semin Immunol 1998; 10: 399-415.
44. Toda M et al. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther 2002; 9: 356-364.
45. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996; 4: 349-355.
46. Huang AY et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264: 961-965.
47. Vile RG et al. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997; 71: 267-274.
48. Todryk S et al. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum Gene Ther 1999; 10: 2757-2768.
49. Ali SA et al. Preclinical evaluation of 'whole' cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes. Cancer Res 2000; 60: 1663-1670.
50. Tolba KA et al. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res 2002; 62: 6545-6551.
51. Kim KJ et al. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 1979; 122: 549-554.
52. Glimcher LH, Kim KJ, Green I, Paul WE. Ia antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells. J Exp Med 1982; 155: 445-459.
53. Johnson PA et al. Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol 1992; 66: 2952-2965.
54. Smith IL, Hardwicke MA, Sandri-Goldin RM. Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology 1992; 186: 74-86.
55. Geller AI, Keyomarsi K, Bryan J, Pardee AB. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci USA 1990; 87: 8950-8954.
56. Bergold PJ, Casaccia-Bonnefil P, Zeng XL, Federoff HJ. Transsynaptic neuronal loss induced in hippocampal slice cultures by a herpes simplex virus vector expressing the GluR6 subunit of the kainate receptor. Proc Natl Acad Sci USA 1993; 90: 6165-6169.
57. Saeki Y et al. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 2001; 3: 591-601.
58. Geschwind MD, Kessler JA, Geller AI, Federoff HJ. Transfer of the nerve growth factor gene into cell lines and cultured neurons using a defective herpes simplex virus vector. Transfer of the NGF gene into cells by a HSV-1 vector. Brain Res Mol Brain Res 1994; 24: 327-335.
59. Levitsky HI et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996; 156: 3858-3865.
60. Zibert A et al. CCL3/MIP-1alpha is a potent immunostimulator when coexpressed with interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine. Hum Gene Ther 2004; 15: 21-34.